Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Walmart Stores Inc (WMT) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Walmart Stores IncTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Walmart Stores Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Walmart Stores Inc trades at $113.69 (market cap $904.83B). The key difference: Walmart Stores Inc is far larger — about 112.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Walmart Stores Inc pays a 0.87% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOWMT
Market Cap
$8.04B$904.83B
Sector
HealthConsumer Staples
52-Week High
$339.75$134.20
52-Week Low
$241.71$95.05
Enterprise Value
$7.85B$968.28B
Volume
5,675,288
Dividend Yield
0.87%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

Walmart Stores Inc

Walmart (WMT) trades at $113.7, down 0.18% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.66 meeting expectations. Revenue grew to $681.0 billion in 2025, with net income reaching $19.44 billion. Analyst consensus is strongly bullish, with a $142.10 price target and 72.72% buy ratings. Recent news highlights operational updates, including drone delivery expansion and AI tool development.

The outlook for WMT is positive, driven by consistent earnings performance and strategic initiatives in e-commerce and technology. Risks include competitive pressures from Amazon, which recently surpassed Walmart in revenue, and potential legal issues from product liability suits. The stock offers a solid dividend and growth potential, but investors should monitor margin pressures and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Walmart Stores Inc

Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.

Read more on WMT